On November 16, 2026, Tempus AI, Inc. entered into a Fifth Amendment to its Master Services Agreement with AstraZeneca AB. The amendment, effective as of January 1, 2027, establishes a new five-year financial commitment period and extends the term of the agreement through December 31, 2031.
Under the terms of the amendment, AstraZeneca has committed to an aggregate of $200 million in fees to be paid to Tempus AI over the Renewal Term. This represents an annual target spend of $40 million across Tempus’s existing and future products and services. The agreement stipulates a minimum annual commitment of $32 million for each calendar year of the Renewal Term.
If the total $200 million aggregate commitment is not met by the end of the Renewal Term, the agreement will be automatically extended by one year, through December 31, 2032, to address any shortfall. AstraZeneca retains the right to terminate the agreement for convenience at any time; however, if termination occurs before the financial commitments are fulfilled, AstraZeneca will be liable for the remaining shortfall.
The filing includes the Fifth Amendment as Exhibit 10.1 to the report.